Elutia (ELUT) Competitors $2.07 -0.08 (-3.72%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. ARCT, CRVS, ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, and NGNEShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Arcturus Therapeutics (NASDAQ:ARCT) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation. Which has stronger valuation & earnings, ARCT or ELUT? Elutia has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M3.48-$80.94M-$2.23-8.74Elutia$24.38M3.49-$53.95M-$1.93-1.07 Does the media prefer ARCT or ELUT? In the previous week, Arcturus Therapeutics had 23 more articles in the media than Elutia. MarketBeat recorded 29 mentions for Arcturus Therapeutics and 6 mentions for Elutia. Elutia's average media sentiment score of 1.88 beat Arcturus Therapeutics' score of 0.42 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ARCT or ELUT more profitable? Arcturus Therapeutics has a net margin of -49.26% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-49.26% -24.87% -17.75% Elutia -168.23%N/A -96.70% Do institutionals & insiders believe in ARCT or ELUT? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer ARCT or ELUT? Arcturus Therapeutics presently has a consensus price target of $50.00, indicating a potential upside of 156.46%. Elutia has a consensus price target of $8.00, indicating a potential upside of 286.47%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ARCT or ELUT? Arcturus Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. SummaryElutia beats Arcturus Therapeutics on 8 of the 15 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.12M$3.14B$5.70B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.0720.7530.6225.55Price / Sales3.49367.71465.58116.50Price / CashN/A43.0338.2159.48Price / Book-1.588.659.026.15Net Income-$53.95M-$54.65M$3.25B$264.98M7 Day Performance2.99%6.66%4.83%2.81%1 Month Performance4.55%9.59%6.81%3.20%1 Year Performance-38.39%14.32%30.56%25.33% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.9538 of 5 stars$2.07-3.7%$8.00+286.5%-34.8%$85.12M$24.38M-1.07180News CoveragePositive NewsEarnings ReportGap DownHigh Trading VolumeARCTArcturus Therapeutics2.8755 of 5 stars$11.39-4.4%$50.80+346.0%+0.1%$323.01M$152.31M-4.50180Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9557 of 5 stars$4.37+1.4%$15.00+243.2%+39.0%$321.15MN/A-4.3330News CoverageAnalyst RevisionABEOAbeona Therapeutics4.2885 of 5 stars$6.28+0.3%$19.25+206.5%+46.1%$320.24M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals1.6493 of 5 stars$4.57-1.5%$24.50+436.1%-56.2%$317.48MN/A-2.2770News CoverageEarnings ReportAnalyst ForecastALDXAldeyra Therapeutics2.2694 of 5 stars$5.25-0.2%$9.50+81.0%+13.0%$315.05MN/A-6.1810News CoverageInsider TradeAnalyst RevisionAMRNAmarin0.2075 of 5 stars$14.94-0.3%$12.00-19.7%+23.0%$310.40M$228.61M-4.07360BNTCBenitec Biopharma1.798 of 5 stars$11.90+0.8%$26.00+118.5%+45.0%$309.76M$80K-7.8820News CoverageRCKTRocket Pharmaceuticals4.8425 of 5 stars$2.92+2.1%$16.33+459.4%-83.4%$308.61MN/A-1.16240Analyst RevisionINBXInhibrx Biosciences2.003 of 5 stars$21.40+1.6%N/A+112.0%$304.86M$200K0.18166News CoverageEarnings ReportShort Interest ↓NGNENeurogene1.9834 of 5 stars$20.35-4.1%$46.17+126.9%-39.8%$302.64M$930K-4.6890News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies ARCT Competitors CRVS Competitors ABEO Competitors OLMA Competitors ALDX Competitors AMRN Competitors BNTC Competitors RCKT Competitors INBX Competitors NGNE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access